Trial · NCT07591584
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating
This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade
- Status
- Recruiting
- Sponsor
- Kiwi Health Inc
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 150 participants (planned)
- Start
- May 4, 2026
- Primary completion
- Oct 26, 2026
- Conditions
- IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Summary
This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating.1 The study's rationale is based on the fact that fermentable carbohydrates (FODMAPs) are often poorly absorbed and can trigger symptoms like bloating and abdominal pain. While a Low FODMAP Diet (LFD) is clinically validated for symptom relief, it is restrictive.
Interventions
- FODMAP-targeting digestive enzyme blend Dietary supplement
- Placebo Other
Locations
1 country: United States.
| Facility | City | Country |
|---|---|---|
| People Science | Los Angeles, California | United States |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.